Host genetic variants in the pathogenesis of hepatitis C

Viruses

Volumn 4, Issue 12, 2012, Pages 3281-3302

  Rau, Monika ^a   Baur, Katharina ^b   Geier, Andreas ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fibrosis progression; Hepatitis C infection; Host genetics; IL28B; SVR

Indexed keywords

ABCB11 PROTEIN; ANTIVIRUS AGENT; CARRIER PROTEIN; DIRECT ACTING ANTIVIRAL DRUG; PEGINTERFERON; RIBAVIRIN; SLC28 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ABCB11 GENE; AP3S2 GENE; AQP2 GENE; AZIN1 GENE; COST CONTROL; CYP27B1 1260 GENE; DEGS1 GENE; DISEASE COURSE; DRUG RESPONSE; DRUG SUBSTITUTION; GC GLOBULIN GENE; GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HEPATITIS C; HOST; HUMAN; IL28B GENE; INOSINE TRIPHOSPHATASE GENE; ITPA GENE; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDICAL DECISION MAKING; MERTK GENE; NONHUMAN; PERSONALIZED MEDICINE; PNPLA3 GENE; PREDICTION; REVIEW; RNF7 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC28A1 GENE; SLC28A2 GENE; SLC28A3 GENE; STXBP5L GENE; TLR4 GENE; TRPM5 GENE; TULP1 GENE; UNSPECIFIED SIDE EFFECT; VDR GENE; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKINS; MEMBRANE TRANSPORT PROTEINS; PYROPHOSPHATASES; RECEPTORS, CALCITRIOL; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84871853264     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4123281     Document Type: Review

References (119)

1. Hepatitis C. Available online: http://www.Who.Int/mediacentre/factsheets/fs164/en/ (accessed on 12 November 2012).
2. Seeff, L.B. Natural history of chronic Hepatitis C. Hepatology 2002, 36, S35-S46.
3. Burra, P. Hepatitis C. Semin. Liver Dis. 2009, 29, 53-65.
4. Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; et al. Genetic variation in il28b predicts Hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
5. Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; et al. Genome-wide association of il28b with response to pegylated interferon-alpha and ribavirin therapy for chronic Hepatitis C. Nat. Genet. 2009, 41, 1105-1109.
6. Suppiah, V.; Moldovan, M.; Ahlenstiel, G.; Berg, T.; Weltman, M.; Abate, M.L.; Bassendine, M.; Spengler, U.; Dore, G.J.; Powell, E.; et al. Il28b is associated with response to chronic Hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41, 1100-1104.
7. Thomas, D.L.; Thio, C.L.; Martin, M.P.; Qi, Y.; Ge, D.; O'Huigin, C.; Kidd, J.; Kidd, K.; Khakoo, S.I.; Alexander, G.; et al. Genetic variation in il28b and spontaneous clearance of Hepatitis C virus. Nature 2009, 461, 798-801.
8. Cavalcante, L.N.; Abe-Sandes, K.; Angelo, A.L.; Machado, T.M.; Lemaire, D.C.; Mendes, C.M.; Pinho, J.R.; Malta, F.; Lyra, L.G.; Lyra, A.C. Il28b polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic Hepatitis C patients from an admixed population. Liver Int. 2012, 32, 476-486.
9. Lyoo, K.; Song, M.J.; Hur, W.; Choi, J.E.; Hong, S.W.; Kim, C.W.; Bae, S.H.; Choi, J.Y.; Choi, S.W.; Shin, E.C.; et al. Polymorphism near the il28b gene in korean Hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J. Clin. Virol. 2011, 52, 363-366.
10. McCarthy, J.J.; Li, J.H.; Thompson, A.; Suchindran, S.; Lao, X.Q.; Patel, K.; Tillmann, H.L.; Muir, A.J.; McHutchison, J.G. Replicated association between an il28b gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138, 2307-2314.
11. Mangia, A.; Thompson, A.J.; Santoro, R.; Piazzolla, V.; Tillmann, H.L.; Patel, K.; Shianna, K.V.; Mottola, L.; Petruzzellis, D.; Bacca, D.; et al. An il28b polymorphism determines treatment response of Hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139, 821-827, e821.
12. Ochi, H.; Maekawa, T.; Abe, H.; Hayashida, Y.; Nakano, R.; Imamura, M.; Hiraga, N.; Kawakami, Y.; Aimitsu, S.; Kao, J.H.; et al. Il-28b predicts response to chronic Hepatitis C therapy-Fine-mapping and replication study in asian populations. J. Gen. Virol. 2011, 92, 1071-1081.
13. Moghaddam, A.; Melum, E.; Reinton, N.; Ring-Larsen, H.; Verbaan, H.; Bjoro, K.; Dalgard, O. Il28b genetic variation and treatment response in patients with Hepatitis C virus genotype 3 infection. Hepatology 2011, 53, 746-754.
14. Asselah, T.; De Muynck, S.; Broet, P.; Masliah-Planchon, J.; Blanluet, M.; Bieche, I.; Lapalus, M.; Martinot-Peignoux, M.; Lada, O.; Estrabaud, E.; et al. Il28b polymorphism is associated with treatment response in patients with genotype 4 chronic Hepatitis C. J. Hepatol. 2012, 56, 527-532.
15. Rauch, A.; Kutalik, Z.; Descombes, P.; Cai, T.; Di Iulio, J.; Mueller, T.; Bochud, M.; Battegay, M.; Bernasconi, E.; Borovicka, J.; et al. Genetic variation in il28b is associated with chronic Hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010, 138, 1338-1345, e1331-e1337.
16. Tillmann, H.L.; Thompson, A.J.; Patel, K.; Wiese, M.; Tenckhoff, H.; Nischalke, H.D.; Lokhnygina, Y.; Kullig, U.; Gobel, U.; Capka, E.; et al. A polymorphism near il28b is associated with spontaneous clearance of acute Hepatitis C virus and jaundice. Gastroenterology 2010, 139, 1586-1592, e1581.
17. Montes-Cano, M.A.; Garcia-Lozano, J.R.; Abad-Molina, C.; Romero-Gomez, M.; Barroso, N.; Aguilar-Reina, J.; Nunez-Roldan, A.; Gonzalez-Escribano, M.F. Interleukin-28b genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52, 33-37.
18. Rao, H.Y.; Sun, D.G.; Jiang, D.; Yang, R.F.; Guo, F.; Wang, J.H.; Liu, F.; Zhang, H.Y.; Zhang, H.H.; Du, S.C.; et al. Il28b genetic variants and gender are associated with spontaneous clearance of Hepatitis C virus infection. J. Viral Hepat. 2012, 19, 173-181.
19. Howell, C.D.; Gorden, A.; Ryan, K.A.; Thompson, A.J.; Ibrahim, C.; Fried, M.; Afdhal, N.H.; McHutchison, J.G.; Shianna, K.V.; Goldstein, D.B.; et al. Single nucleotide polymorphism upstream of interleukin 28b associated with phase 1 and phase 2 of early viral kinetics in patients infected with hcv genotype 1. J. Hepatol. 2012, 56, 557-563.
20. Arends, J.E.; Fransen, J.H.; Hoepelman, A.I.; van Baarle, D. Association between il28b polymorphisms and first-phase viral load decrease in chronic Hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. Int. J. Antimicrob. Agents 2011, 38, 538-539.
21. Bochud, P.Y.; Bibert, S.; Negro, F.; Haagmans, B.; Soulier, A.; Ferrari, C.; Missale, G.; Zeuzem, S.; Pawlotsky, J.M.; Schalm, S.; et al. Il28b polymorphisms predict reduction of hcv rna from the first day of therapy in chronic Hepatitis C. J. Hepatol. 2011, 55, 980-988.
22. Lindh, M.; Lagging, M.; Arnholm, B.; Eilard, A.; Nilsson, S.; Norkrans, G.; Soderholm, J.; Wahlberg, T.; Wejstal, R.; Westin, J.; et al. Il28b polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic Hepatitis C genotype 1. J. Viral Hepat. 2011, 18, e325-331.
23. Abe, H.; Hayes, C.N.; Ochi, H.; Tsuge, M.; Miki, D.; Hiraga, N.; Imamura, M.; Takahashi, S.; Kubo, M.; Nakamura, Y.; et al. Inverse association of il28b genotype and liver mrna expression of genes promoting or suppressing antiviral state. J. Med. Virol. 2011, 83, 1597-1607.
24. Lopez-Rodriguez, R.; Trapero-Marugan, M.; Borque, M.J.; Roman, M.; Hernandez-Bartolome, A.; Rodriguez-Munoz, Y.; Martin-Vilchez, S.; Abad-Santos, F.; Munoz de Rueda, P.; Vidal-Castineira, J.R.; et al. Genetic variants of interferon-stimulated genes and il-28b as host prognostic factors of response to combination treatment for chronic Hepatitis C. Clin. Pharmacol. Ther. 2011, 90, 712-721.
25. Scott, J.; Holte, S.; Urban, T.; Burgess, C.; Coppel, E.; Wang, C.; Corey, L.; McHutchison, J.; Goldstein, D. Il28b genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat Hepatitis C virus infection. J. Infect. Dis. 2011, 204, 419-425.
26. Younossi, Z.M.; Birerdinc, A.; Estep, M.; Stepanova, M.; Afendy, A.; Baranova, A. The impact of il28b genotype on the gene expression profile of patients with chronic Hepatitis C treated with pegylated interferon alpha and ribavirin. J. Transl. Med. 2012, 10, 25.
27. Pearlman, B.L.; Ehleben, C. The il-28b genotype predicts which slow-responding hepatitis c-infected patients will benefit from treatment extension. Am. J. Gastroenterol. 2011, 106, 1370-1371.
28. Scherzer, T.M.; Stattermayer, A.F.; Strasser, M.; Laferl, H.; Maieron, A.; Stauber, R.; Datz, C.; Dulic-Lakovic, E.; Steindl-Munda, P.; Hofer, H.; et al. Impact of il28b on treatment outcome in Hepatitis C virus g1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40kd)/ribavirin. Hepatology 2011, 54, 1518-1526.
29. Mangia, A.; Thompson, A.J.; Santoro, R.; Piazzolla, V.; Copetti, M.; Minerva, N.; Petruzzellis, D.; Mottola, L.; Bacca, D.; McHutchison, J.G. Limited use of interleukin 28b in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 54, 772-780.
30. Fischer, J.; Bohm, S.; Scholz, M.; Muller, T.; Witt, H.; George, J.; Sarrazin, C.; Susser, S.; Schott, E.; Suppiah, V.; et al. Combined effects of different interleukin-28b gene variants on the outcome of dual combination therapy in chronic Hepatitis C virus type 1 infection. Hepatology 2012, 55, 1700-1710.
31. Thompson, A.J.; Muir, A.J.; Sulkowski, M.S.; Ge, D.; Fellay, J.; Shianna, K.V.; Urban, T.; Afdhal, N.H.; Jacobson, I.M.; Esteban, R.; et al. Interleukin-28b polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 Hepatitis C virus. Gastroenterology 2010, 139, 120-129, e118.
32. Halfon, P.; Bourliere, M.; Ouzan, D.; Maor, Y.; Renou, C.; Wartelle, C.; Penaranda, G.; Tran, A.; Botta, D.; Oules, V.; et al. A single il28b genotype snp rs12979860 determination predicts treatment response in patients with chronic Hepatitis C genotype 1 virus. Eur. J. Gastroenterol. Hepatol. 2011, 23, 931-935.
33. Akuta, N.; Suzuki, F.; Hirakawa, M.; Kawamura, Y.; Yatsuji, H.; Sezaki, H.; Suzuki, Y.; Hosaka, T.; Kobayashi, M.; Saitoh, S.; et al. Amino acid substitution in Hepatitis C virus core region and genetic variation near the interleukin 28b gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52, 421-429.
34. Tsubota, A.; Shimada, N.; Yoshizawa, K.; Furihata, T.; Agata, R.; Yumoto, Y.; Abe, H.; Ika, M.; Namiki, Y.; Chiba, K.; et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for hcv genotype 1b patients. Liver Int. 2012, 32, 826-836.
35. Gal-Tanamy, M.; Bachmetov, L.; Ravid, A.; Koren, R.; Erman, A.; Tur-Kaspa, R.; Zemel, R. Vitamin D: An innate antiviral agent suppressing Hepatitis C virus in human hepatocytes. Hepatology 2011, 54, 1570-1579.
36. Bitetto, D.; Fattovich, G.; Fabris, C.; Ceriani, E.; Falleti, E.; Fornasiere, E.; Pasino, M.; Ieluzzi, D.; Cussigh, A.; Cmet, S.; et al. Complementary role of Vitamin D deficiency and the interleukin-28b rs12979860 c/t polymorphism in predicting antiviral response in chronic Hepatitis C. Hepatology 2011, 53, 1118-1126.
37. Kawaoka, T.; Hayes, C.N.; Ohishi, W.; Ochi, H.; Maekawa, T.; Abe, H.; Tsuge, M.; Mitsui, F.; Hiraga, N.; Imamura, M.; et al. Predictive value of the il28b polymorphism on the effect of interferon therapy in chronic Hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 2011, 54, 408-414.
38. Takita, M.; Hagiwara, S.; Arizumi, T.; Hayaishi, S.; Ueda, T.; Kitai, S.; Yada, N.; Inoue, T.; Minami, Y.; Chung, H.; et al. Association of interleukin-28b and Hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. Digestion 2011, 84, 56-61.
39. Honda, M.; Sakai, A.; Yamashita, T.; Nakamoto, Y.; Mizukoshi, E.; Sakai, Y.; Nakamura, M.; Shirasaki, T.; Horimoto, K.; Tanaka, Y.; et al. Hepatic isg expression is associated with genetic variation in interleukin 28b and the outcome of ifn therapy for chronic Hepatitis C. Gastroenterology 2010, 139, 499-509.
40. Miyamura, T.; Kanda, T.; Nakamoto, S.; Wu, S.; Fujiwara, K.; Imazeki, F.; Yokosuka, O. Hepatic stat1-nuclear translocation and interleukin 28b polymorphisms predict treatment outcomes in Hepatitis C virus genotype 1-infected patients. PLoS One 2011, 6, e28617.
41. Toyoda, H.; Kumada, T.; Tada, T.; Hayashi, K.; Honda, T.; Katano, Y.; Goto, H.; Kawaguchi, T.; Murakami, Y.; Matsuda, F. Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the il28b gene in patients infected with hcv genotype 1b. J. Med. Virol. 2012, 84, 61-70.
42. Huang, C.F.; Huang, J.F.; Yang, J.F.; Hsieh, M.Y.; Lin, Z.Y.; Chen, S.C.; Wang, L.Y.; Juo, S.H.; Chen, K.C.; Chuang, W.L.; et al. Interleukin-28b genetic variants in identification of Hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J. Hepatol. 2012, 56, 34-40.
43. Kurosaki, M.; Tanaka, Y.; Nishida, N.; Sakamoto, N.; Enomoto, N.; Honda, M.; Sugiyama, M.; Matsuura, K.; Sugauchi, F.; Asahina, Y.; et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic Hepatitis C using genetic polymorphism in il28b and viral factors. J. Hepatol. 2011, 54, 439-448.
44. D'Avolio, A.; Ciancio, A.; Siccardi, M.; Baietto, L.; Simiele, M.; Patanella, S.; Marucco, D.A.; Cariti, G.; Calcagno, A.; Sciandra, M.; et al. Slc28a2 65c > t predict sustained virological response in patients with Hepatitis C treated with interferon and ribavirin, considering all hcv genotype and genotype 1/4. J. Hepatol. 2010, 52, S463-S463.
45. Rau, M.; Weisskopf, M.; Stickel, F.; Schmitt, J.; Russmann, S.; Dill, M.T.; Dufour, J.F.; Moradpou, D.; Negro, F.; Semela, D.; et al. Impact of genetic concentrative nucleoside transporter variants on peg-interferon/ribavirin therapy response and ribavirin serum levels in Hepatitis C patients. J. Hepatol. 2012, 56, S455-S456.
46. Doehring, A.; Hofmann, W.P.; Schlecker, C.; Zeuzem, S.; Sarrazin, C.; Berg, T.; Muller, T.; Herrmann, E.; Geisslinger, G.; Lotsch, J. Role of nucleoside transporters slc28a2/3 and slc29a1/2 genetics in ribavirin therapy: Protection against anemia in patients with chronic Hepatitis C. Pharmacogenetics Genom. 2011, 21, 289-296.
47. Fellay, J.; Thompson, A.J.; Ge, D.; Gumbs, C.E.; Urban, T.J.; Shianna, K.V.; Little, L.D.; Qiu, P.; Bertelsen, A.H.; Watson, M.; et al. Itpa gene variants protect against anaemia in patients treated for chronic Hepatitis C. Nature 2010, 464, 405-408.
48. Sakamoto, N.; Tanaka, Y.; Nakagawa, M.; Yatsuhashi, H.; Nishiguchi, S.; Enomoto, N.; Azuma, S.; Nishimura-Sakurai, Y.; Kakinuma, S.; Nishida, N.; et al. Itpa gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for japanese patients with chronic Hepatitis C. Hepatol. Res. 2010, 40, 1063-1071.
49. Kurosaki, M.; Tanaka, Y.; Tanaka, K.; Suzuki, Y.; Hoshioka, Y.; Tamaki, N.; Kato, T.; Yasui, Y.; Hosokawa, T.; Ueda, K.; et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir. Ther. 2011, 16, 685-694.
50. Tanaka, Y.; Kurosaki, M.; Nishida, N.; Sugiyama, M.; Matsuura, K.; Sakamoto, N.; Enomoto, N.; Yatsuhashi, H.; Nishiguchi, S.; Hino, K.; et al. Genome-wide association study identified itpa/ddrgk1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic Hepatitis C. Hum. Mol. Genet. 2011, 20, 3507-3516.
51. Baur, K.; Mertens, J.C.; Schmitt, J.; Iwata, R.; Stieger, B.; Frei, P.; Seifert, B.; Bischoff Ferrari, H.A.; von Eckardstein, A.; Mullhaupt, B.; et al. The Vitamin D receptor gene bat (cca) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic Hepatitis C patients. Antivir. Ther. 2012, 17, 541-547.
52. Lange, C.M.; Bojunga, J.; Ramos-Lopez, E.; von Wagner, M.; Hassler, A.; Vermehren, J.; Herrmann, E.; Badenhoop, K.; Zeuzem, S.; Sarrazin, C. Vitamin D deficiency and a cyp27b1-1260 promoter polymorphism are associated with chronic Hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol. 2011, 54, 887-893.
53. Lange, C.M.; Bibert, S.; Kutalik, Z.; Burgisser, P.; Cerny, A.; Dufour, J.F.; Geier, A.; Gerlach, T.J.; Heim, M.H.; Malinverni, R.; et al. A genetic validation study reveals a role of Vitamin D metabolism in the response to interferon-alfa-based therapy of chronic Hepatitis C. PLoS One 2012, 7, e40159.
54. Falleti, E.; Bitetto, D.; Fabris, C.; Fattovich, G.; Cussigh, A.; Cmet, S.; Ceriani, E.; Fornasiere, E.; Pasino, M.; Ieluzzi, D.; et al. Vitamin D binding protein gene polymorphisms and baseline Vitamin D levels as predictors of antiviral response in chronic Hepatitis C. Hepatology 2012, 56, 1641-1650.
55. Iwata, R.; Stieger, B.; Mertens, J.C.; Muller, T.; Baur, K.; Frei, P.; Braun, J.; Vergopoulos, A.; Martin, I.V.; Schmitt, J.; et al. The role of bile acid retention and a common polymorphism in the abcb11 gene as host factors affecting antiviral treatment response in chronic Hepatitis C. J. Viral Hepat. 2011, 18, 768-778.
56. Kubitz, R.; Brinkmeyer, C.; Sagir, A.; Herebian, D.; Haussinger, D. Genetic variants of the bile salt export pump: Inducers and modifiers of liver diseases. Dig. Dis. 2011, 29, 89-92.
57. De Nicola, S.; Aghemo, A.; Rumi, M.G.; Galmozzi, E.; Valenti, L.; Soffredini, R.; De Francesco, R.; Prati, G.M.; D'Ambrosio, R.; Cheroni, C.; et al. Interleukin 28b polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic Hepatitis C genotype 4. Hepatology 2012, 55, 336-342.
58. Feld, J.J.; Nanda, S.; Huang, Y.; Chen, W.; Cam, M.; Pusek, S.N.; Schweigler, L.M.; Theodore, D.; Zacks, S.L.; Liang, T.J.; et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007, 46, 1548-1563.
59. Sarasin-Filipowicz, M.; Oakeley, E.J.; Duong, F.H.; Christen, V.; Terracciano, L.; Filipowicz, W.; Heim, M.H. Interferon signaling and treatment outcome in chronic Hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7034-7039.
60. Ferenci, P.; Fried, M.W.; Shiffman, M.L.; Smith, C.I.; Marinos, G.; Goncales, F.L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; et al. Predicting sustained virological responses in chronic Hepatitis C patients treated with peginterferon alfa-2a (40 kd)/ribavirin. J. Hepatol. 2005, 43, 425-433.
61. Easl clinical practice guidelines: Management of Hepatitis C virus infection. J. Hepatol. 2011, 55, 245-264.
62. Ghany, M.G.; Nelson, D.R.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. An update on treatment of genotype 1 chronic Hepatitis C virus infection: 2011 practice guideline by the american association for the study of liver diseases. Hepatology 2011, 54, 1433-1444.
63. Bognar, F. Il28b polymorphism predicts virologic response in patients with Hepatitis C genotype 1 treated with boceprevir (boc) combination therapy. J. Gastroenterol. Hepatol. 2011, 26, 19-20.
64. Bronowicki, J.P.; Hezode, C.; Bengtsson, L.; Pol, S.; Bourliere, M.; Serfaty, L.; de Ledinghen, V.; Tran, A.; Benhamou, Y.; Grange, J.D.; et al. 100% svr in il28b cc patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the prove2 trial. J. Hepatol. 2012, 56, S430-S431.
65. Fried, M.W.; Buti, M.; Dore, G.J.; Ferenci, P.; Jacobson, I.; Marcellin, P.; Zeuzem, S.; Lenz, O.; Peeters, M.; Sekar, V.J.; et al. Efficacy and safety of tmc435 in combination with peginterferon alpha-2a and ribavirin in treatment-naive genotype-1 hcv patients: 24-week interim results from the pillar study. Hepatology 2010, 52, 403A-404A.
66. Hayes, C.N.; Abe, H.; Miki, D.; Ochi, H.; Karino, Y.; Toyota, J.; Sezaki, H.; Kobayashi, M.; Akuta, N.; Suzuki, F.; et al. Il28b but not itpa polymorphism is associated with response to peg-interferon, ribavirin and telaprevir triple therapy in patients with Hepatitis C virus genotype 1. Hepatology 2011, 54, 832A-832A.
67. McHutchison, J.G.; Goldstein, D.B.; Shianna, K.; Lawitz, E.; Lalezari, J.P.; Rodriguez-Torres, M.; Kowdley, K.V.; Nelson, D.; DeJesus, E.; Symonds, W.; et al. Il28b snp geographical distribution and antiviral responses in a 28-day phase 2a trial of psi-7977 daily dosing plus peg-ifn/rbv. Hepatology 2010, 52, 711A-711A.
68. Penney, M.S.; De Souza, C.; Seepersaud, S.; Alves, K.; Koziel, M.J.; Kauffman, R.S.; Di Bisceglie, A.M.; Botfield, M.C.; Grp, Z.S. All il28b genotypes have high svr rates in patients treated with vx-222 in combination with telaprevir/peginterferon/ribavirin in the zenith study. J. Hepatol. 2012, 56, S476-S477.
69. Poordad, F.; Bronowicki, J.-P.; Gordon, S.C.; Zeuzem, S.; Jacobson, I.M.; Sulkowski, M.; Poynard, T.; Morgan, T.R.; Burroughs, M.; Sniukiene, V.; et al. Il28b polymorphism predicts virologic response in patients with Hepatitis C genotype 1 treated with boceprevir (boc) combination therapy. Gastroenterology 2011, 140, S941-S941.
70. Chu, T.W.; Kulkarni, R.; Gane, E.J.; Roberts, S.K.; Stedman, C.; Angus, P.W.; Ritchie, B.; Lu, X.Y.; Ipe, D.; Lopatin, U.; et al. Effect of il28b genotype on early viral kinetics during interferon-free treatment of patients with chronic Hepatitis C. Gastroenterology 2012, 142, 790-795.
71. Lawitz, E.; Poordad, F.; Kowdley, K.V.; Jensen, D.; Cohen, D.E.; Siggelkow, S.; Wikstrom, K.; Larsen, L.; Menon, R.M.; Podsadecki, T.; et al. A 12-week interferon-free regimen of abt-450/r, abt-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive hcv il28b-cc genotype-1-infected subjects. J. Hepatol. 2012, 56, S7-S7.
72. Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.P.; Lohse, A.; Muellhaupt, B.; Schuchmann, M.; Bourliere, M.; Buti, M.; Roberts, S.; et al. Svr4 and svr12 with an interferon-free regimen of bi201335 and bi207127, +/-ribavirin, in treatment-naive patients with chronic genotype-1 hcv infection: Interim results of sound-c2. J. Hepatol. 2012, 56, S45-S45.
73. Thompson, A.J.; Fellay, J.; Patel, K.; Tillmann, H.L.; Naggie, S.; Ge, D.; Urban, T.J.; Shianna, K.V.; Muir, A.J.; Fried, M.W.; et al. Variants in the itpa gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010, 139, 1181-1189.
74. Matsumura, T.; Kato, T.; Sugiyama, N.; Tasaka-Fujita, M.; Murayama, A.; Masaki, T.; Wakita, T.; Imawari, M. 25-hydroxyVitamin D(3) suppresses Hepatitis C virus production. Hepatology 2012, 56, 1231-1239.
75. Petta, S.; Camma, C.; Scazzone, C.; Tripodo, C.; Di Marco, V.; Bono, A.; Cabibi, D.; Licata, G.; Porcasi, R.; Marchesini, G.; et al. Low Vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic Hepatitis C. Hepatology 2010, 51, 1158-1167.
76. Abu-Mouch, S.; Fireman, Z.; Jarchovsky, J.; Zeina, A.R.; Assy, N. Vitamin D supplementation improves sustained virologic response in chronic Hepatitis C (genotype 1)-naive patients. World J. Gastroenterol. 2011, 17, 5184-5190.
77. Nimer, A.; Mouch, A. Vitamin D improves viral response in Hepatitis C genotype 2-3 naive patients. World J. Gastroenterol. 2012, 18, 800-805.
78. Chang, K.O.; George, D.W. Bile acids promote the expression of Hepatitis C virus in replicon-harboring cells. J. Virol. 2007, 81, 9633-9640.
79. Scholtes, C.; Diaz, O.; Icard, V.; Kaul, A.; Bartenschlager, R.; Lotteau, V.; Andre, P. Enhancement of genotype 1 Hepatitis C virus replication by bile acids through fxr. J. Hepatol. 2008, 48, 192-199.
80. Jorquera, F.; Monte, M.J.; Guerra, J.; Sanchez-Campos, S.; Merayo, J.A.; Olcoz, J.L.; Gonzalez-Gallego, J.; Marin, J.J. Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic Hepatitis C. J. Gastroenterol. Hepatol. 2005, 20, 547-554.
81. Lebovics, E.; Seif, F.; Kim, D.; Elhosseiny, A.; Dworkin, B.M.; Casellas, A.; Clark, S.; Rosenthal, W.S. Pruritus in chronic Hepatitis C: Association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig. Dis. Sci. 1997, 42, 1094-1099.
82. Meier, Y.; Zodan, T.; Lang, C.; Zimmermann, R.; Kullak-Ublick, G.A.; Meier, P.J.; Stieger, B.; Pauli-Magnus, C. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331t>c polymorphism in the bile salt export pump. World J. Gastroenterol. 2008, 14, 38-45.
83. Marabita, F.; Aghemo, A.; De Nicola, S.; Rumi, M.G.; Cheroni, C.; Scavelli, R.; Crimi, M.; Soffredini, R.; Abrignani, S.; De Francesco, R.; et al. Genetic variation in the interleukin-28b gene is not associated with fibrosis progression in patients with chronic Hepatitis C and known date of infection. Hepatology 2011, 54, 1127-1134.
84. Falleti, E.; Bitetto, D.; Fabris, C.; Cussigh, A.; Fornasiere, E.; Cmet, S.; Fumolo, E.; Bignulin, S.; Fontanini, E.; Cerutti, A.; et al. Role of interleukin 28b rs12979860 c/t polymorphism on the histological outcome of chronic Hepatitis C: Relationship with gender and viral genotype. J. Clin. Immunol. 2011, 31, 891-899.
85. Fabris, C.; Falleti, E.; Cussigh, A.; Bitetto, D.; Fontanini, E.; Colletta, C.; Vandelli, C.; Cmet, S.; Ceriani, E.; Smirne, C.; et al. The interleukin 28b rs12979860 c/t polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic Hepatitis C and persistently normal transaminases. J. Med. Virol. 2012, 84, 747-755.
86. Abe, H.; Ochi, H.; Maekawa, T.; Hayes, C.N.; Tsuge, M.; Miki, D.; Mitsui, F.; Hiraga, N.; Imamura, M.; Takahashi, S.; et al. Common variation of il28 affects gamma-gtp levels and inflammation of the liver in chronically infected Hepatitis C virus patients. J. Hepatol. 2010, 53, 439-443.
87. Bochud, P.Y.; Bibert, S.; Kutalik, Z.; Patin, E.; Guergnon, J.; Nalpas, B.; Goossens, N.; Kuske, L.; Mullhaupt, B.; Gerlach, T.; et al. Il28b alleles associated with poor Hepatitis C virus (hcv) clearance protect against inflammation and fibrosis in patients infected with non-1 hcv genotypes. Hepatology 2012, 55, 384-394.
88. Baur, K.; Mertens, J.C.; Schmitt, J.; Iwata, R.; Stieger, B.; Eloranta, J.J.; Frei, P.; Stickel, F.; Dill, M.T.; Seifert, B.; et al. Combined effect of 25-oh Vitamin D plasma levels and genetic Vitamin D receptor (nr 1i1) variants on fibrosis progression rate in hcv patients. Liver Int. 2012, 32, 635-643.
89. Iwata, R.; Baur, K.; Stieger, B.; Mertens, J.C.; Daly, A.K.; Frei, P.; Braun, J.; Vergopoulos, A.; Stickel, F.; Sabrane, K.; et al. A common polymorphism in the abcb11 gene is associated with advanced fibrosis in Hepatitis C but not in non-alcoholic fatty liver disease. Clin. Sci. (Lond.) 2011, 120, 287-296.
90. Valenti, L.; Maggioni, P.; Piperno, A.; Rametta, R.; Pelucchi, S.; Mariani, R.; Dongiovanni, P.; Fracanzani, A.L.; Fargion, S. Patatin-like phospholipase domain containing-3 gene i148m polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J. Gastroenterol. 2012, 18, 2813-2820.
91. Trepo, E.; Pradat, P.; Potthoff, A.; Momozawa, Y.; Quertinmont, E.; Gustot, T.; Lemmers, A.; Berthillon, P.; Amininejad, L.; Chevallier, M.; et al. Impact of patatin-like phospholipase-3 (rs738409 c>g) polymorphism on fibrosis progression and steatosis in chronic Hepatitis C. Hepatology 2011, 54, 60-69.
92. Patin, E.; Kutalik, Z.; Guergnon, J.; Bibert, S.; Nalpas, B.; Jouanguy, E.; Munteanu, M.; Bousquet, L.; Argiro, L.; Halfon, P.; et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from hcv infection. Gastroenterology 2012, 143, 1244-1252. e12.
93. Lichtinghagen, R.; Bahr, M.J.; Wehmeier, M.; Michels, D.; Haberkorn, C.I.; Arndt, B.; Flemming, P.; Manns, M.P.; Boeker, K.H. Expression and coordinated regulation of matrix metalloproteinases in chronic Hepatitis C and Hepatitis C virus-induced liver cirrhosis. Clin. Sci. (Lond.) 2003, 105, 373-382.
94. Terrier, B.; Carrat, F.; Geri, G.; Pol, S.; Piroth, L.; Halfon, P.; Poynard, T.; Souberbielle, J.C.; Cacoub, P. Low 25-oh Vitamin D serum levels correlate with severe fibrosis in hiv-hcv co-infected patients with chronic hepatitis. J. Hepatol. 2011, 55, 756-761.
95. Ramm, G.A.; Shepherd, R.W.; Hoskins, A.C.; Greco, S.A.; Ney, A.D.; Pereira, T.N.; Bridle, K.R.; Doecke, J.D.; Meikle, P.J.; Turlin, B.; et al. Fibrogenesis in pediatric cholestatic liver disease: Role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009, 49, 533-544.
96. Mullenbach, R.; Weber, S.N.; Krawczyk, M.; Zimmer, V.; Sarrazin, C.; Lammert, F.; Gunhage, F. A frequent variant in the human bile salt export pump gene abcb11 is associated with Hepatitis C virus infection, but not liver stiffness in a german population. BMC Gastroenterol. 2012, 12, 63.
97. Many, N.; Stickel, F.; Schmitt, J.; Stieger, B.; Soyka, M.; Frei, P.; Gotze, O.; Mullhaupt, B.; Geier, A. Genetic variations in bile acid homeostasis are not overrepresented in alcoholic cirrhosis compared to patients with heavy alcohol abuse and absent liver disease. Mutagenesis 2012, 27, 567-572.
98. Falleti, E.; Fabris, C.; Vandelli, C.; Colletta, C.; Cussigh, A.; Smirne, C.; Fontanini, E.; Cmet, S.; Minisini, R.; Bitetto, D.; et al. Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic Hepatitis C. Hum. Immunol. 2010, 71, 999-1004.
99. Fontana, R.J.; Litman, H.J.; Dienstag, J.L.; Bonkovsky, H.L.; Su, G.; Sterling, R.K.; Lok, A.S. Ykl-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic Hepatitis C. Liver Int. 2012, 32, 665-674.
100. Dai, C.Y.; Chuang, W.L.; Chang, W.Y.; Chen, S.C.; Lee, L.P.; Hsieh, M.Y.; Hou, N.J.; Lin, Z.Y.; Huang, J.F.; Wang, L.Y.; et al. Tumor necrosis factor-alpha promoter polymorphism at position-308 predicts response to combination therapy in Hepatitis C virus infection. J. Infect. Dis. 2006, 193, 98-101.
101. Dai, C.Y.; Chuang, W.L.; Hsieh, M.Y.; Lee, L.P.; Hou, N.J.; Chen, S.C.; Lin, Z.Y.; Wang, L.Y.; Tsai, J.F.; Chang, W.Y.; et al. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic Hepatitis C. Transl. Res. 2006, 148, 128-133.
102. Fabris, C.; Vandelli, C.; Toniutto, P.; Minisini, R.; Colletta, C.; Falleti, E.; Smirne, C.; Pirisi, M. Apolipoprotein e genotypes modulate fibrosis progression in patients with chronic Hepatitis C and persistently normal transaminases. J. Gastroenterol. Hepatol. 2011, 26, 328-333.
103. Falleti, E.; Cmet, S.; Fabris, C.; Bitetto, D.; Cussigh, A.; Fornasiere, E.; Bignulin, E.; Feruglio, C.; Mosanghini, E.; Fontanini, E.; et al. Association between the epidermal growth factor rs4444903 g/g genotype and advanced fibrosis at a young age in chronic Hepatitis C. Cytokine 2012, 57, 68-73.
104. Hellier, S.; Frodsham, A.J.; Hennig, B.J.; Klenerman, P.; Knapp, S.; Ramaley, P.; Satsangi, J.; Wright, M.; Zhang, L.; Thomas, H.C.; et al. Association of genetic variants of the chemokine receptor ccr5 and its ligands, rantes and mcp-2, with outcome of hcv infection. Hepatology 2003, 38, 1468-1476.
105. Hennig, B.J.; Hellier, S.; Frodsham, A.J.; Zhang, L.; Klenerman, P.; Knapp, S.; Wright, M.; Thomas, H.C.; Thursz, M.; Hill, A.V. Association of low-density lipoprotein receptor polymorphisms and outcome of Hepatitis C infection. Genes Immun. 2002, 3, 359-367.
106. Knapp, S.; Hennig, B.J.; Frodsham, A.J.; Zhang, L.; Hellier, S.; Wright, M.; Goldin, R.; Hill, A.V.; Thomas, H.C.; Thursz, M.R. Interleukin-10 promoter polymorphisms and the outcome of Hepatitis C virus infection. Immunogenetics 2003, 55, 362-369.
107. Nalpas, B.; Lavialle-Meziani, R.; Plancoulaine, S.; Jouanguy, E.; Nalpas, A.; Munteanu, M.; Charlotte, F.; Ranque, B.; Patin, E.; Heath, S.; et al. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic Hepatitis C infection. Gut 2010, 59, 1120-1126.
108. Paris, A.J.; Snapir, Z.; Christopherson, C.D.; Kwok, S.Y.; Lee, U.E.; Ghiassi-Nejad, Z.; Kocabayoglu, P.; Sninsky, J.J.; Llovet, J.M.; Kahana, C.; et al. A polymorphism that delays fibrosis in Hepatitis C promotes alternative splicing of azin1, reducing fibrogenesis. Hepatology 2011, 54, 2198-2207.
109. Silva, G.F.; Grotto, R.M.; Verdichio-Moraes, C.F.; Corvino, S.M.; Ferrasi, A.C.; Silveira, L.V.; Pardini, M.I. Human platelet antigen genotype is associated with progression of fibrosis in chronic Hepatitis C. J. Med. Virol. 2012, 84, 56-60.
110. Tulio, S.; Faucz, F.R.; Werneck, R.I.; Olandoski, M.; Alexandre, R.B.; Boldt, A.B.; Pedroso, M.L.; de Messias-Reason, I.J. Masp2 gene polymorphism is associated with susceptibility to Hepatitis C virus infection. Hum. Immunol. 2011, 72, 912-915.
111. Wasmuth, H.E.; Tag, C.G.; Van de Leur, E.; Hellerbrand, C.; Mueller, T.; Berg, T.; Puhl, G.; Neuhaus, P.; Samuel, D.; Trautwein, C.; et al. The marburg i variant (g534e) of the factor vii-activating protease determines liver fibrosis in Hepatitis C infection by reduced proteolysis of platelet-derived growth factor bb. Hepatology 2009, 49, 775-780.
112. Wiederholt, T.; von Westernhagen, M.; Zaldivar, M.M.; Berres, M.L.; Schmitz, P.; Hellerbrand, C.; Muller, T.; Berg, T.; Trautwein, C.; Wasmuth, H.E. Genetic variations of the chemokine scavenger receptor d6 are associated with liver inflammation in chronic Hepatitis C. Hum. Immunol. 2008, 69, 861-866.
113. Wright, M.; Goldin, R.; Hellier, S.; Knapp, S.; Frodsham, A.; Hennig, B.; Hill, A.; Apple, R.; Cheng, S.; Thomas, H.; et al. Factor v leiden polymorphism and the rate of fibrosis development in chronic Hepatitis C virus infection. Gut 2003, 52, 1206-1210.
114. Hillebrandt, S.; Wasmuth, H.E.; Weiskirchen, R.; Hellerbrand, C.; Keppeler, H.; Werth, A.; Schirin-Sokhan, R.; Wilkens, G.; Geier, A.; Lorenzen, J.; et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 2005, 37, 835-843.
115. Huang, H.; Shiffman, M.L.; Friedman, S.; Venkatesh, R.; Bzowej, N.; Abar, O.T.; Rowland, C.M.; Catanese, J.J.; Leong, D.U.; Sninsky, J.J.; et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic Hepatitis C. Hepatology 2007, 46, 297-306.
116. Marcolongo, M.; Young, B.; Dal Pero, F.; Fattovich, G.; Peraro, L.; Guido, M.; Sebastiani, G.; Palu, G.; Alberti, A. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic Hepatitis C. Hepatology 2009, 50, 1038-1044.
117. Pradat, P.; Trepo, E.; Potthoff, A.; Bakshi, R.; Young, B.; Trepo, C.; Lagier, R.; Moreno, C.; Lemmers, A.; Gustot, T.; et al. The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic Hepatitis C. Hepatology 2010, 51, 356-357.
118. Trepo, E.; Potthoff, A.; Pradat, P.; Bakshi, R.; Young, B.; Lagier, R.; Moreno, C.; Verset, L.; Cross, R.; Degre, D.; et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in Hepatitis C patients with minimal liver disease. J. Hepatol. 2011, 55, 38-44.
119. Curto, T.M.; Lagier, R.J.; Lok, A.S.; Everhart, J.E.; Rowland, C.M.; Sninsky, J.J. Predicting cirrhosis and clinical outcomes in patients with advanced chronic Hepatitis C with a panel of genetic markers (crs7). Pharmacogenet. Genom. 2011, 21, 851-860.